Understanding Breast Cancer Risk and Screening in Individuals on Hormone Therapy Through a Pilot Breast Cancer Screening Program
This investigation is a prospective breast cancer screening study open to all individuals on hormone therapy. Using a mixed methods approach, the study will 1) gather prospective quantitative breast imaging data in conjunction with hormone therapy and family cancer history and 2) investigate individuals on hormone therapy perceptions and experiences in the breast cancer screening program, and 3) identify individual and systems-level barriers to breast cancer screening.
• Males 40-75 years of age with a history of ≥9 months of estrogen and/or progesterone hormone therapy.
• Females 40-75 years of age with any history of testosterone hormone therapy, with or without cosmetic mastectomy, but have not undergone complete mastectomy.
• Persons who have undergone breast cancer screening before can participate.
• Individuals who meet criteria for above eligibility and are ≥30-39 years of age with a 1st or 2nd degree family member with breast cancer.
• Ability to speak, read, and write in English.
• Ability to understand a written informed consent document, and the willingness to sign it.
• Board-certified radiologist that specializes in breast imaging and are an actively employed faculty member at Froedtert \& the Medical College of Wisconsin (main campus location).
• Part of the breast radiology faculty who read both ABUS and MMG of the study participants.
• Ability to speak, read, and write in English.
• Ability to understand a written informed consent document, and the willingness to sign it.
• Must be either a technician, nurse, or clerical staff that works with the breast radiology team at Froedtert \& the Medical College of Wisconsin (main campus location).
• Ability to understand a written informed consent document, and the willingness to sign it.
• Ability to speak, read, and write in English.